3 Research Driven Pharma Company, Instrument Clusters Maker and Multi Speciality Hospital Network Stocks With a Strong Future Roadmap: Glenmark Pharmaceuticals, Pricol and Fortis Healthcare

Research drug, dashboard part, hospital stocks bring together companies with a visible plan for the years ahead. Glenmark Pharmaceuticals, Pricol and Fortis Healthcare cover a research driven pharma company, an instrument clusters maker and a multi speciality hospital network.

This list covers three research drug, dashboard part, hospital stocks with complete current figures: Glenmark Pharmaceuticals, Pricol and Fortis Healthcare. Every figure comes from the latest reported financials and the 5 November 2026 market close. Companies without complete current figures were left out.

Click Here – Get Free Investment Predictions

What Are Research Drug, Dashboard Part, Hospital Stocks?

Research drug, dashboard part, hospital stocks are listed companies that develop and sell branded generics and specialty medicines, make instrument clusters and driver information systems for vehicles, and run multi-speciality hospitals across India. Their earnings depend on drug approvals, vehicle output and patient volumes.

Research Drug, Dashboard Part, Hospital Stocks at a Glance

On valuation, all three trade at a P/E below their industry P/E, which means the market is pricing them at a lower multiple than their peer group. Readers comparing research drug, dashboard part, hospital stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain. With the Q2 FY27 results season close, investors in research drug, dashboard part, hospital stocks can use the coming numbers to test whether growth is holding.

Why Do Research Drug, Dashboard Part, Hospital Stocks Have a Strong Roadmap in India?

Research drug, dashboard part, hospital stocks have a strong roadmap in India because wider demand for specialty medicines, rising vehicle electronics content and growing demand for advanced care keep widening the market for these companies.

• Pharma. Specialty medicines reach more markets.
• Instrument clusters. Modern vehicles carry digital displays.
• Hospitals. Patients seek advanced care.

Why Glenmark Pharmaceuticals Features Among These Research Drug, Dashboard Part, Hospital Stocks

Among the research drug, dashboard part, hospital stocks on this list, Glenmark Pharmaceuticals is a research-driven pharma company with branded generics in India and other emerging markets, generics in the United States and Europe, and an innovation arm focused on new drugs.

Revenue rose from Rs 12,472 crore in FY22 to Rs 17,443 crore in FY26, a compound annual growth rate of 8.7%. Net profit grew from Rs 994 crore in FY22 to Rs 1,362 crore in FY26, which works out to a compound annual growth rate of 8.2%.

In the June 2026 quarter, revenue grew 24.1% year on year to Rs 4,084 crore. The company has a return on equity of 28.1%, a debt to equity ratio of 0.06 and a market capitalisation of Rs 60,103 crore. The stock trades at a P/E of 33.4, below the industry P/E of 35.7.

Roadmap: The company is strengthening its dermatology and respiratory franchises and advancing its innovation pipeline, which could add higher-value income. Growth in India and emerging markets supports steady sales.

What to watch: Track new product launches, progress in the innovation pipeline and balance sheet strength.

Why Pricol Features Among These Research Drug, Dashboard Part, Hospital Stocks

Among the pharma, auto part and health shares on this list, Pricol, based in Coimbatore, makes instrument clusters, driver information systems, sensors and pumps for two-wheelers, commercial vehicles and off-highway vehicles.

In the June 2026 quarter, revenue grew 23.4% year on year to Rs 1,108 crore, while net profit rose 34.3% to Rs 67.0 crore. Revenue rose from Rs 1,554 crore in FY22 to Rs 4,052 crore in FY26, a compound annual growth rate of 27.1%.

Net profit grew from Rs 51.1 crore in FY22 to Rs 251 crore in FY26, which works out to a compound annual growth rate of 48.8%. The company has a return on equity of 20.0%, a debt to equity ratio of 0.30 and a market capitalisation of Rs 8,072 crore. The stock trades at a P/E of 30.1, below the industry P/E of 36.9.

Roadmap: Digital clusters and connected vehicle systems carry higher value per vehicle than the analogue gauges they replace. Pricol is also expanding into electric vehicle components and exports, and widening its non-auto business to reduce cyclicality.

What to watch: Track the shift to digital clusters and the progress of new product ramp-ups.

Why Fortis Healthcare Features Among These Research Drug, Dashboard Part, Hospital Stocks

Among the three companies on this list, Fortis Healthcare operates a network of multi-specialty hospitals across India, with strengths in cardiac sciences, oncology, neurosciences and orthopaedics, and it also runs a diagnostics business.

The company has a return on equity of 10.5%, a debt to equity ratio of 0.35 and a market capitalisation of Rs 55,554 crore. The stock trades at a P/E of 51.9, below the industry P/E of 59.6.

Revenue rose from Rs 5,745 crore in FY22 to Rs 9,178 crore in FY26, a compound annual growth rate of 12.4%. Net profit grew from Rs 790 crore in FY22 to Rs 1,064 crore in FY26, which works out to a compound annual growth rate of 7.7%. In the June 2026 quarter, revenue grew 17.3% year on year to Rs 2,560 crore, while net profit rose 2.3% to Rs 273 crore.

Roadmap: The company is adding beds at existing hospitals and building new capacity in cities where demand for advanced care is rising. Its diagnostics arm and a growing share of complex procedures widen the earnings base beyond routine admissions.

What to watch: Track bed additions, occupancy and revenue per occupied bed.

Glenmark Pharmaceuticals vs Pricol vs Fortis Healthcare on Key Financials

The table below sets the three research drug, dashboard part, hospital stocks side by side on revenue, profit and margin, using reported figures.

Glenmark Pharmaceuticals posts the highest return on equity in this group at 28.1%. Glenmark Pharmaceuticals has the largest FY26 revenue at Rs 17,443 crore, and Pricol shows the fastest revenue growth with a 27.1% compound annual rate. A useful habit with research drug, dashboard part, hospital stocks is to check each new quarterly result against the capacity plans the company described earlier.

The June 2026 quarter, the latest reported, gives a fresh read on momentum:

Key Risks to Check Before Investing in Research Drug, Dashboard Part, Hospital Stocks

Every theme carries risks that deserve a check before any decision. For these research drug, dashboard part, hospital stocks, the main points are: Long-term pharma, auto part and health shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.

• Regulatory approvals. Plant inspections and approvals can affect supplies.
• Capacity ramp up. New hospitals take time to fill beds and reach full returns.
• Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them.

Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.

Use the Univest Stock Screener to filter research drug, dashboard part, hospital stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.

Final Thoughts on Research Drug, Dashboard Part, Hospital Stocks

Research drug, dashboard part, hospital stocks suit investors who prefer to study business strength before price moves. Glenmark Pharmaceuticals, Pricol and Fortis Healthcare each have a clear plan to grow. Based on the 5 November 2026 close, Glenmark Pharmaceuticals trades at Rs 2,481.8, Pricol at Rs 727.9 and Fortis Healthcare at Rs 819.8. Valuation matters as much as growth, so compare each company's P/E with its industry P/E before adding any of these research drug, dashboard part, hospital stocks to a watchlist.

Download the Univest iOS App or Univest Android App to track research drug, dashboard part, hospital stocks, set price alerts and get research-backed stock ideas.

What are research drug, dashboard part, hospital stocks?

Ans. Research drug, dashboard part, hospital stocks are listed companies that develop and sell branded generics and specialty medicines, make instrument clusters and driver information systems for vehicles, and run multi-speciality hospitals across India. Their earnings depend on drug approvals, vehicle output and patient volumes. This list looks at three of them, Glenmark Pharmaceuticals, Pricol and Fortis Healthcare, using reported FY22 to FY26 financials and the 5 November 2026 closing prices.

Which research drug, dashboard part, hospital stocks are covered in this list?

Ans. This list covers Glenmark Pharmaceuticals, Pricol and Fortis Healthcare. Based on the 5 November 2026 close, Glenmark Pharmaceuticals traded at Rs 2,481.8, Pricol at Rs 727.9 and Fortis Healthcare at Rs 819.8. Their return on equity ranges from 10.5% to 28.1%, and their revenue compound annual growth from FY22 to FY26 ranges from 8.7% to 27.1%.

Why do research drug, dashboard part, hospital stocks have a strong future roadmap in India?

Ans. Research drug, dashboard part, hospital stocks have a strong roadmap in India because wider demand for specialty medicines, rising vehicle electronics content and growing demand for advanced care keep widening the market for these companies. The main drivers are as follows. Pharma. Specialty medicines reach more markets. Instrument clusters. Modern vehicles carry digital displays. Hospitals. Patients seek advanced care. Together these factors give the companies on this list a visible path for growth over the coming years.

How has Glenmark Pharmaceuticals performed financially?

Ans. Revenue rose from Rs 12,472 crore in FY22 to Rs 17,443 crore in FY26, a compound annual growth rate of 8.7%. Net profit grew from Rs 994 crore in FY22 to Rs 1,362 crore in FY26, which works out to a compound annual growth rate of 8.2%. In the June 2026 quarter, revenue grew 24.1% year on year to Rs 4,084 crore. The company has a return on equity of 28.1%, a debt to equity ratio of 0.06 and a market capitalisation of Rs 60,103 crore. The stock trades at a P/E of 33.4, below the industry P/E of 35.7. Looking ahead, the company is strengthening its dermatology and respiratory franchises and advancing its innovation pipeline, which could add higher-value income. Growth in India and emerging markets supports steady sales.

How has Pricol performed financially?

Ans. Revenue rose from Rs 1,554 crore in FY22 to Rs 4,052 crore in FY26, a compound annual growth rate of 27.1%. Net profit grew from Rs 51.1 crore in FY22 to Rs 251 crore in FY26, which works out to a compound annual growth rate of 48.8%. In the June 2026 quarter, revenue grew 23.4% year on year to Rs 1,108 crore, while net profit rose 34.3% to Rs 67.0 crore. The company has a return on equity of 20.0%, a debt to equity ratio of 0.30 and a market capitalisation of Rs 8,072 crore. The stock trades at a P/E of 30.1, below the industry P/E of 36.9. Looking ahead, digital clusters and connected vehicle systems carry higher value per vehicle than the analogue gauges they replace. Pricol is also expanding into electric vehicle components and exports, and widening its non-auto business to reduce cyclicality.

How has Fortis Healthcare performed financially?

Ans. Revenue rose from Rs 5,745 crore in FY22 to Rs 9,178 crore in FY26, a compound annual growth rate of 12.4%. Net profit grew from Rs 790 crore in FY22 to Rs 1,064 crore in FY26, which works out to a compound annual growth rate of 7.7%. In the June 2026 quarter, revenue grew 17.3% year on year to Rs 2,560 crore, while net profit rose 2.3% to Rs 273 crore. The company has a return on equity of 10.5%, a debt to equity ratio of 0.35 and a market capitalisation of Rs 55,554 crore. The stock trades at a P/E of 51.9, below the industry P/E of 59.6. Looking ahead, the company is adding beds at existing hospitals and building new capacity in cities where demand for advanced care is rising. Its diagnostics arm and a growing share of complex procedures widen the earnings base beyond routine admissions.

What risks should investors check before buying research drug, dashboard part, hospital stocks?

Ans. Investors should check a few risks before buying research drug, dashboard part, hospital stocks. Regulatory approvals. Plant inspections and approvals can affect supplies. Capacity ramp up. New hospitals take time to fill beds and reach full returns. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.

Is this list of research drug, dashboard part, hospital stocks investment advice?

Ans. No. This article is educational and uses publicly available data as of the 5 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.